MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
MacroGenics reported Q1 2026 revenue of $20.8 million, a 57.5% increase from the same period in 2025. The company announced the divestiture of its manufacturing operations to Bora Pharmaceuticals, which is expected to provide an upfront payment of $122.5 million and extend its cash runway through 2028. MacroGenics also expanded its ZYNYZ royalty monetization with Sagard Healthcare Partners, receiving $60.0 million and potentially up to $20.0 million more based on 2026 sales performance.
Key figures
- Eps Beat
- 0
- Revenue
- 20775000
- Guidance
- Cash runway extended through 2028, based on anticipated closing of manufacturing divestiture and additional payments from partners
- Revenue Yoy
- 57.5%
- Total assets
- 217873000
- Deferred revenue
- 67993000
- Shares outstanding
- 63560068
- Total stockholders equity
- 21198000
- Zynyz royalty monetization
- 60000000
- Potential additional milestone
- 20000000
- Manufacturing divestiture proceeds
- 122500000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.